Acer Therapeutics Inc.
Acer Therapeutics Inc. (ACER): 3 pipeline candidates · ~1 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.5 months
D/E -1.29 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Acer Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$595K
Quarterly Burn
$14.4M
Runway
0.5 mo
Revenue
$372K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Acer Therapeutics Inc.'s pipeline?
Acer Therapeutics Inc. (ACER) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Acer Therapeutics Inc.'s lead drug candidate?
Acer Therapeutics Inc.'s most advanced tracked candidate is acer-801 (Phase 2) for Vasomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer.
What is Acer Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Acer Therapeutics Inc. has approximately 0.5 months of cash runway.
Who is the CEO of Acer Therapeutics Inc.?
Schelling Founder is the chief executive officer of Acer Therapeutics Inc. (ACER).
Get the full picture on Acer Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.